Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
Feb. 25, 2021—A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes.
May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.
Mar. 23, 2017—Rene Raphemot, Ph.D., a National Institutes of Health postdoctoral fellow at Duke University, delivered the inaugural Discovery Science Emerging Scholars Lecture at Vanderbilt University School of Medicine last week.
Dec. 1, 2016—In a new study, Vanderbilt pharmacologist Jerod Denton, Ph.D., Ohio State entomologist Peter Piermarini, Ph.D., and colleagues report an experimental molecule that inhibits kidney function in mosquitoes and thus might provide a new way to control the deadliest animal on Earth.
Dec. 10, 2015—Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement.
Apr. 16, 2014—A new compound that activates potassium channels could be used to treat disorders of glucose homeostasis.
May. 31, 2013—Researchers are targeting a possible new weapon in the fight against malaria, science that could also be applied in the fight against other devastating mosquito-borne illnesses, according to a Vanderbilt study published in PLOS ONE.
Feb. 3, 2012—Vanderbilt researcher and Gabon, Africa, native is working to discover ways to kill malaria-spreading mosquitoes.